Tenvie Therapeutics Launches with $200 Million to Deliver Breakthrough Small Molecule Therapies
Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases Led by expert R&D leadership team...
Year: 2025
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
Bitterroot Bio Reports Data on Safety and Target Engagement from Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers
BRB-002 was safe at all doses tested, with no SAEs reportedPhase 2 proof-of-concept study in patients with established atherosclerosis is...
Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
BETHESDA, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
COUR Pharmaceuticals Secures FDA Orphan Drug Designation for CNP-104 in Primary Biliary Cholangitis
CHICAGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed to induce...
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of cutaneous venous malformations...
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
– Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both...
DiagnaMed and QIMC to Advance Hydrogen Production Technology at the Ville Marie Clean Natural Renewable Hydrogen Project
A Strategic collaboration to Accelerate Clean Natural Hydrogen InnovationTORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or...
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will...
Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors
SANTA CRUZ, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to...
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective...
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option...
Atsena Therapeutics Initiates Part B of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisis
Part B of the LIGHTHOUSE study will enroll adults and childrenDURHAM, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics,...
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology
23andMe is helping collaborators better understand disease biology, identify novel targets, boost clinical trial success, and engage people in their...
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
Study AER-01-002 is using a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary disease (COPD)...
Dentsply Sirona to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CHARLOTTE, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced...
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/...
BlackfinBio Ltd announces the acquisition of Parkinson’s IP patent portfolio from OXB
SHEFFIELD, United Kingdom, Jan. 8, 2025 /PRNewswire/ -- BlackfinBio Ltd (BFB) a clinical stage gene therapy company focused on the development...